We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Alliance for Neurodegenerative Diagnostics

By Labmedica staff writers
Posted on 08 Apr 2005
Print article
A collaborative research agreement has been announced by Power3 Medical Products, Inc. (The Woodlands, TX, USA) and New Horizons Diagnostics Corp. (Columbia, MD, USA) for the development of antibody-based diagnostic tests for neurodegenerative disease, using the protein biomarkers of Power3 Medical.

Power3 has discovered a method of employing a series of tests for the differential diagnosis of neurodegenerative diseases utilizing blood serum, which was co-developed by neurologist Dr. Stan Appel, professor of neurology at Baylor College of Medicine (Houston, TX, USA), Dr. Ira L. Goldknopf, chief scientific officer of Power3 Medical, and their respective teams.

Power3 Medical intends to develop a series of tests that involve monitoring the concentration of panels of proteins in the blood. The company has discovered unique groups of biomarkers whose profiles are relatively sensitive and specific in distinguishing patients with amyotrophic lateral sclerosis (ALS), Alzheimer's disease (AD), and Parkinson's disease from each other, as well as from normal patients and patients with other neurologic disorders. In all, Power3 has identified 34 biomarkers for neurodegenerative diseases.

New Horizons Diagnostics will utilize specifically tailored monoclonal and polyclonal antibodies to the biomarkers, which will be incorporated into immunoassays. Once the assays are available, New Horizons will then develop and validate diagnostic tests on their platform, which is specifically designed to detect and discriminate among the neurodegenerative diseases.

"New Horizons Diagnostics has been successfully involved in test platform development before, but none of these projects are as important or timely as the collaboration with Power3,” observed Lawrence Loomis, president of New Horizons. "With an aging population and new therapies available, early detection is paramount. We are excited to have been chosen to be part of this elite team to make a new age of diagnostics available.”



Related Links:
Power3 Medical
New Horizons
Gold Member
Blood Gas Analyzer
GEM Premier 7000 with iQM3
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Anti-Secukinumab ELISA
LISA-TRACKER anti-Secukinumab
New
PSA Test
Human Semen Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.